<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363997</url>
  </required_header>
  <id_info>
    <org_study_id>GDN 005/16</org_study_id>
    <nct_id>NCT03363997</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days</brief_title>
  <official_title>A Randomized, Open-label Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days in Healthy, Post-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galeno Desenvolvimento de Pesquisas Clínicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SocraTec R&amp;D GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galeno Desenvolvimento de Pesquisas Clínicas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluated the pharmacokinetics and pharmacodynamics of estriol in healthy&#xD;
      post-menopausal women after the application of one vaginal ring containing one of three&#xD;
      different dosages of estriol (100 mg (Test 1), 300 mg (Test 2) or 600 mg (Test 3)) with&#xD;
      continuous delivery (0.125, 0.250 or 0.500 mg/day) for 21 days. And also, characterized its&#xD;
      safety and tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase I, single center, open-label, randomised (allocation to treatment), balanced,&#xD;
      single dose trial was performed in a parallel-group design. The subjects were randomly&#xD;
      assigned to one of the 3 possible treatments (single vaginal application of 1 vaginal ring&#xD;
      containing 100, 300 or 600 mg estriol, with delivery rate of 0.125, 0.250 or 0.500 mg/day&#xD;
      over 21 days.&#xD;
&#xD;
      Blood samples were collected at 0.5 h prior to drug application, 1, 2, 4, 6, 12, 24, 48, 96,&#xD;
      144, 216, 288, 360, 432 h after application; 5 min prior to removal, i.e., 21 d after&#xD;
      application (study day 22), as well as 6, 12 and 24 h after removal to characterise&#xD;
      pharmacokinetic parameters of estriol in plasma.&#xD;
&#xD;
      Serum concentrations of follicle stimulating hormone (FSH), luteinising hormone (LH) and sex&#xD;
      hormone binding globulin (SHBG) and gynaecological parameters (cytology of vaginal smear, the&#xD;
      maturation index and the vaginal pH) were evaluated as pharmacodynamic parameters.&#xD;
&#xD;
      The safety and tolerability was assessed by endometrial thickness and documentation of&#xD;
      adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2016</start_date>
  <completion_date type="Actual">June 6, 2017</completion_date>
  <primary_completion_date type="Actual">December 15, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of estriol plasma levels</measure>
    <time_frame>0-22 days</time_frame>
    <description>Blood sampling for the determination of plasma levels of estriol in participants of each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of estriol</measure>
    <time_frame>0-22 days</time_frame>
    <description>Determination of Cmax for estriol based on plasma concentrations of samples obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for estriol</measure>
    <time_frame>0-22 days</time_frame>
    <description>Calculation of the AUC for estriol based on plasma concentrations of samples obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterisation of follicle stimulating hormone (FSH)</measure>
    <time_frame>0-22 days</time_frame>
    <description>Determination of serum concentrations of FSH under the three treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterisation of luteinising hormone (LH)</measure>
    <time_frame>0-22 days</time_frame>
    <description>Determination of serum concentrations of LH under the three treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterisation of sex hormone binding globulin (SHBG)</measure>
    <time_frame>0-22 days</time_frame>
    <description>Determination of serum concentrations of SHBG under the three treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterisation of cytology of vaginal smear</measure>
    <time_frame>0-22 days</time_frame>
    <description>Characterisation of cytology of vaginal smear (parabasal, intermediate and superficial cells) under the three treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of maturation index</measure>
    <time_frame>0-22 days</time_frame>
    <description>Calculation of maturation index under the three treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of vaginal pH</measure>
    <time_frame>0-22 days</time_frame>
    <description>Determination of vaginal pH under the three treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events per participant</measure>
    <time_frame>up to 22days after treatment</time_frame>
    <description>Number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests results.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Test 1 vaginal ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single vaginal application of 1 vaginal ring containing 100 mg estriol, with delivery rate of 0.125 mg/day over 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2 vaginal ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single vaginal application of 1 vaginal ring containing 300 mg estriol, with delivery rate of 0.250 mg/day over 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 3 vaginal ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single vaginal application of 1 vaginal ring containing 600 mg estriol, with delivery rate of 0.500 mg/day over 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol 0.125 mg/day</intervention_name>
    <description>Application of one vaginal ring</description>
    <arm_group_label>Test 1 vaginal ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol 0.250 mg/day</intervention_name>
    <description>Application of one vaginal ring</description>
    <arm_group_label>Test 2 vaginal ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol 0.500 mg/day</intervention_name>
    <description>Application of one vaginal ring</description>
    <arm_group_label>Test 3 vaginal ring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body-mass index (BMI) ≥18.5 kg/m² and ≤ 30.0 kg/m²&#xD;
&#xD;
          -  Postmenopausal state: FSH (plasma) ≥ 40 IU/l, estradiol (serum) ≤ 20 pg/ml last&#xD;
             spontaneous menstruation at least 12 months ago&#xD;
&#xD;
          -  Normal transvaginal endometrial scan (endometrial thickness &lt; 5 mm)&#xD;
&#xD;
          -  Good state of health&#xD;
&#xD;
          -  Non-smoker or ex-smoker for at least 6 month&#xD;
&#xD;
          -  Written informed consent, after having been informed about benefits and potential&#xD;
             risks of the clinical trial, as well as details of the insurance taken out to cover&#xD;
             the subjects participating in the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Existing cardiac, hepatic and/or haematological diseases or pathological findings,&#xD;
             which might interfere with the safety or tolerability and/or pharmacokinetics and/or&#xD;
             pharmacodynamics of the active ingredient&#xD;
&#xD;
          -  History of relevant central nervous system (CNS) and/or psychiatric disorders and/or&#xD;
             currently treated CNS and/or psychiatric disorders&#xD;
&#xD;
          -  Known allergic reactions to the active ingredients used or to constituents of the&#xD;
             pharmaceutical preparations&#xD;
&#xD;
          -  Subjects with severe allergies or multiple drug allergies, unless it is judged as not&#xD;
             relevant for the clinical trial by the investigator&#xD;
&#xD;
          -  Positive anti-HIV-test (if positive to be verified by western blot), HBs-AG-test (if&#xD;
             positive to be verified by test for HBc-IgM) or anti-HCV-test&#xD;
&#xD;
          -  Presence or history of venous or arterial thrombosis (e.g. deep venous thrombosis,&#xD;
             pulmonary embolism)&#xD;
&#xD;
          -  Known, past or suspected breast cancer or increased familiar risk for development&#xD;
&#xD;
          -  Known or suspected estrogen-dependent malignant tumours (e.g. endometrial or breast&#xD;
             cancer)&#xD;
&#xD;
          -  Undiagnosed genital bleeding&#xD;
&#xD;
          -  Acute vaginal infection or other diseases prohibiting the placement of vaginal ring&#xD;
&#xD;
          -  History of endometrial hyperplasia&#xD;
&#xD;
          -  Migraine or frequent episodes of severe headache&#xD;
&#xD;
          -  History of or current drug or alcohol dependence&#xD;
&#xD;
          -  Subjects who are on a diet which could affect the pharmacokinetics of the active&#xD;
             ingredient&#xD;
&#xD;
          -  Regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day&#xD;
&#xD;
          -  Blood donation or other blood loss of more than 400 ml within the last 3 months prior&#xD;
             to individual enrolment of the subject&#xD;
&#xD;
          -  Participation in a clinical trial during the last 6 months prior to individual&#xD;
             enrolment of the subject&#xD;
&#xD;
          -  Concomitant systemic therapy with antibiotics, which might interfere with&#xD;
             enterohepatic recirculation (e.g. cephalosporines, neomycin, ampicillin or&#xD;
             tetracyclines)&#xD;
&#xD;
          -  Use of sex hormones within 6 months (oral, transdermal, vaginal) or 8 months&#xD;
             (intramuscular administered depot preparations used once per month) or 12 months&#xD;
             (intramuscular administered depot preparations used once per 3 months) before&#xD;
             screening&#xD;
&#xD;
          -  Use of systemic or topical medications or substances which oppose the study objectives&#xD;
             or which might influence them within 8 weeks before screening examination&#xD;
&#xD;
          -  Subjects who are unable to understand the written and verbal instructions, in&#xD;
             particular regarding the risks and inconveniences they will be exposed to during their&#xD;
             participation in the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilberto De Nucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Galeno Desenvolvimento de Pesquisas Clinicas Ltda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Galeno Desenvolvimento de Pesquisas Clínicas</investigator_affiliation>
    <investigator_full_name>Gilberto De Nucci</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>estriol</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>hormone replacement therapy</keyword>
  <keyword>vaginal ring administration</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

